Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$8.35 +1.8%	$9.21	$6.01 ▼ $11.31	$1.72B	1.1	3.66 million shs	2.31 million shs
FOLD Amicus Therapeutics	$6.98 +4.8%	$6.15	$5.51 ▼ $12.65	$2.05B	0.53	4.37 million shs	3.25 million shs
LGND Ligand Pharmaceuticals	$152.69 +3.9%	$124.13	$93.58 ▼ $156.53	$2.84B	0.85	259,130 shs	1.77 million shs
ZBIO Zenas BioPharma	$15.90 +6.7%	$12.34	$5.83 ▼ $26.25	$623.54M	N/A	138,024 shs	98,042 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	+1.83%	-0.12%	-4.68%	-15.23%	+8.02%
FOLD Amicus Therapeutics	+4.80%	-0.14%	+14.61%	+18.71%	-39.72%
LGND Ligand Pharmaceuticals	+3.86%	+12.98%	+25.46%	+45.29%	+53.30%
ZBIO Zenas BioPharma	+6.71%	-1.18%	+42.22%	+83.18%	+1,589,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.0995 of 5 stars	3.5	2.0	4.2	3.1	1.7	0.6
FOLD Amicus Therapeutics	3.9028 of 5 stars	3.4	1.0	4.3	2.1	0.0	1.9
LGND Ligand Pharmaceuticals	3.4084 of 5 stars	1.5	1.0	4.4	2.5	2.5	1.9
ZBIO Zenas BioPharma	1.4862 of 5 stars	3.5	0.0	0.0	1.9	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.90	Moderate Buy	$16.70	100.00% Upside
FOLD Amicus Therapeutics	2.80	Moderate Buy	$16.22	132.41% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$157.00	2.82% Upside
ZBIO Zenas BioPharma	3.00	Buy	$36.67	130.61% Upside

Current Analyst Ratings Breakdown

Latest ZBIO, LGND, FOLD, and BCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	LGND Ligand Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$155.00 ➝ $185.00
8/4/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
7/30/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$145.00 ➝ $162.00
7/17/2025	FOLD Amicus Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
7/1/2025	BCRX BioCryst Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
5/16/2025	ZBIO Zenas BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/15/2025	ZBIO Zenas BioPharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$35.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	3.89	N/A	N/A	($2.01) per share	-4.15
FOLD Amicus Therapeutics	$528.29M	4.07	N/A	N/A	$0.66 per share	10.58
LGND Ligand Pharmaceuticals	$167.13M	17.62	$1.67 per share	91.49	$42.94 per share	3.56
ZBIO Zenas BioPharma	$5M	133.02	N/A	N/A	$7.48 per share	2.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.18	N/A	N/A	1.86	-6.41%	N/A	-1.78%	N/A
FOLD Amicus Therapeutics	-$56.11M	-$0.12	N/A	16.23	N/A	-6.67%	-5.07%	-1.23%	N/A
LGND Ligand Pharmaceuticals	-$4.03M	-$4.00	N/A	41.16	N/A	-40.44%	-9.21%	-8.09%	N/A
ZBIO Zenas BioPharma	-$156.99M	-$3.55	N/A	∞	N/A	N/A	N/A	N/A	8/21/2025 (Estimated)

Latest ZBIO, LGND, FOLD, and BCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	ZBIO Zenas BioPharma	-$1.02	N/A	N/A	N/A	$1.25 million	N/A
8/12/2025	Q2 2025	ZBIO Zenas BioPharma	-$1.02	-$1.25	-$0.23	-$1.25	N/A	N/A
8/7/2025	Q2 2025	LGND Ligand Pharmaceuticals	$1.54	$1.60	+$0.06	$0.24	$43.87 million	$47.63 million
8/4/2025	Q2 2025	BCRX BioCryst Pharmaceuticals	$0.03	$0.15	+$0.12	$0.02	$149.59 million	$163.35 million
5/15/2025	Q1 2025	ZBIO Zenas BioPharma	-$1.15	-$0.80	+$0.35	-$0.80	$5.00 million	$10.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.25	2.22
FOLD Amicus Therapeutics	1.92	3.21	2.29
LGND Ligand Pharmaceuticals	N/A	5.45	5.21
ZBIO Zenas BioPharma	N/A	6.47	6.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
FOLD Amicus Therapeutics	N/A
LGND Ligand Pharmaceuticals	91.28%
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	5.10%
FOLD Amicus Therapeutics	2.20%
LGND Ligand Pharmaceuticals	7.00%
ZBIO Zenas BioPharma	16.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.92 million	199.21 million	Optionable
FOLD Amicus Therapeutics	480	308.24 million	301.46 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable
ZBIO Zenas BioPharma	N/A	41.83 million	34.93 million	N/A

ZBIO, LGND, FOLD, and BCRX Headlines

Recent News About These Companies

Zenas BioPharma Reports Q2 2025 Financial Results

3 hours ago | tipranks.com

Zenas BioPharma expects cash to fund operations into Q4 of 2026

August 12 at 10:42 PM | msn.com

Zenas BioPharma reports Q2 EPS ($1.25) vs ($24.23) last year

August 12 at 4:31 PM | msn.com

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 12 at 7:05 AM | globenewswire.com

44,067 Shares in Zenas BioPharma, Inc. (NASDAQ:ZBIO) Purchased by Jefferies Financial Group Inc.

August 9, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 8.8% - Should You Sell?

August 6, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 10.2% - What's Next?

August 5, 2025 | marketbeat.com

3 Highly Shorted Stocks That Could Be the Next Wall Street Sensations

August 2, 2025 | msn.com

Zenas BioPharma (NASDAQ:ZBIO) Trading Up 5.3% - Here's Why

July 29, 2025 | marketbeat.com

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

July 28, 2025 | seekingalpha.com

Zenas BioPharma (NASDAQ:ZBIO) Shares Down 6.5% - Time to Sell?

July 26, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 11.2% - Here's Why

July 14, 2025 | marketbeat.com

Innovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharma

July 3, 2025 | tipranks.com

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 20, 2025 | globenewswire.com

ZBIO DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 ...

June 17, 2025 | stockhouse.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

June 17, 2025 | prnewswire.com

Investors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)

June 16, 2025 | accessnewswire.comA

ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 16, 2025 | globenewswire.com

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

June 16, 2025 | globenewswire.com

June 16, 2025 Deadline: Join Class Action Lawsuit Against Zenas BioPharma, Inc. (ZBIO) - Contact Levi & Korsinsky

June 16, 2025 | accessnewswire.comA

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

June 16, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZBIO, LGND, FOLD, and BCRX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.35 +0.15 (+1.83%)

Closing price 08/12/2025 04:00 PM Eastern

Extended Trading

$8.36 +0.01 (+0.07%)

As of 08/12/2025 07:45 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Amicus Therapeutics NASDAQ:FOLD

$6.98 +0.32 (+4.80%)

Closing price 08/12/2025 04:00 PM Eastern

Extended Trading

$6.94 -0.04 (-0.57%)

As of 08/12/2025 07:54 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Ligand Pharmaceuticals NASDAQ:LGND

$152.69 +5.68 (+3.86%)

Closing price 08/12/2025 04:00 PM Eastern

Extended Trading

$152.78 +0.09 (+0.06%)

As of 08/12/2025 07:58 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Zenas BioPharma NASDAQ:ZBIO

$15.90 +1.00 (+6.71%)

As of 08/12/2025 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time